Platinum Priority – EditorialReferring to the article published on pp. 961–964 of this issuePersonalised Medicine for Advanced Urothelial Cancer: What is the Right Way to Identify the Right Patient for the Right Treatment?
Referring to the article published on pp. 961–964 of this issue
References (10)
- et al.
From clinical trials to real-life clinical practice: the role of immunotherapy with PD-1/PD-L1 inhibitors in advanced urothelial carcinoma
Eur Urol Oncol
(2018) - et al.
Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy
Eur Urol
(2017) - et al.
The Cancer Genome Atlas expression subtypes stratify response to checkpoint inhibition in advanced urothelial cancer and identify a subset of patients with high survival probability
Eur Urol
(2019) - et al.
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Lancet
(2017) - et al.
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Lancet
(2016)
There are more references available in the full text version of this article.
Cited by (3)
Epigenetic and Immunological Features of Bladder Cancer
2023, International Journal of Molecular Sciences
© 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.